Intended for healthcare professionals

CCBYNC Open access

Rapid response to:


Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study

BMJ 2009; 339 doi: (Published 23 September 2009) Cite this as: BMJ 2009;339:b3569

Rapid Response:

Questions about research

Einarson suggests that studies by Malm and Davis were selectively
omitted in the data in the meta-analysis highlighted in my response. This
is not the case. The Forest Plot figures clearly show the studies by Malm
and Davis referred to. The question about why Einarson's groups data was
not included in their meta-analysis should be addressed to GSK. Why this
data was not included in the meta-analysis is puzzling, as it was
available at the time and they have previously provided funding for
Einarsons work. (1)

This meta-analysis helps see the wood among the trees of the single
underpowered studies. The point of the original letter is that this would
appear to be a class effect of SSRI antidepressants. These data need to be
clearly communicated to women using or considering using this class of
drugs in order that they can make informed decisions.

1 Einarson Editors Note on error re disclosures Am J Psychiatry
165;11, November 2008 p1488

Competing interests:
Competing interests declared in previous response

Competing interests: No competing interests

03 October 2009
Derelie Mangin
Associate Professor, Director Primary Care Research Unit
Department of Public Health and General Practice,University of Otago, Christchurch